Cadrenal Therapeutics, Inc. — Form 8-K
Filed August 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cadrenal announced positive feedback from July 28, 2026 Type D FDA meeting on CAD-1005, a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia. FDA agreed on optimized primary endpoint (proportion of SRA-positive patients with new/worsening thromboembolic events through Day 14 or discharge) and placebo-controlled trial design. The indication targets ~50,000 annual acute HIT cases in US with estimated $2B peak annual revenue opportunity.
Why this rating
Regulatory clarity on Phase 3 design materially de-risks lead program for $24.9M company; FDA alignment on endpoint is critical gate before trial launch; $2B peak revenue claim and orphan designations support commercial optionality, though execution risk remains high.
Price action (we called it positive)
before filing · preread $1.50 ▼ 2.60% | at our read · unknown $1.54 | +10 min · unknown $1.54 ▲ 0.00% | +30 min · unknown $1.54 ▲ 0.00% | +1 hr pending | +4 hrs pending |
The stock had already moved +2.67% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from August 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.